Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.